Radiation and immunotherapy for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer (or hormone-receptor low breast cancer not helped by hormone therapy) that cannot be surgically removed or has spread.
- You have not received any chemotherapy for advanced or metastatic breast cancer yet.
- You are physically active enough to be up and moving (ECOG score 0 or 1).
- You have 1 to 5 tumors that can be treated with radiation, each between 0.5 cm and 5 cm in size, and at least one tumor outside the radiation field that can be measured.
- Your blood counts, liver, and kidney function are within safe ranges as checked by your doctor.
- If you have brain metastases, they are either not needing treatment right now or can be treated with the radiation used in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, the immunotherapy drug pembrolizumab, and low or high-dose radiation before surgery for people with triple-negative breast cancer that has spread to the lymph nodes. The goal is to see if this approach can improve treatment outcomes.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests a new way to treat triple-negative breast cancer before surgery by combining radiation therapy with an immunotherapy drug and chemotherapy. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Hear when a new Triple-Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.